AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KAUG 136 min read$RMTI

Rockwell Medical Announces Second Quarter 2026 Results

ROCKWELL MEDICAL, INC. (RMTI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Rockwell Medical Announces Second Quarter 2026 Results • Net Sales for the second quarter 2026 were $17.8 million, an increase over net sales for the first quarter 2026 and an 11% increase over the same period in 2025 • Gross Profit for the second quarter 2026 increased 30% over

Original reporting
SEC EDGAR 8-K
Published Aug 13, 2026, 10:14 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 10:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$RMTI
Bullish
medium confidence
Mentioned
$RMTI
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$RMTIBullishMed
01

Why it matters

Traders can reassess the probability of meeting 2026 targets using the newly reported Q2 sales growth, gross margin expansion, and operating cash flow, alongside the company’s reiterated guidance ranges.

02

Market read

Fresh quarterly financials plus reiterated full-year guidance provide a decision point for positioning in a small-cap healthcare name.

03

What to watch

Reverse split history and Nasdaq compliance regain could affect liquidity and investor positioning, and the guidance ranges may still be sensitive to customer purchasing variability.

Relevance 7/10Novelty 7/10Timing: pre-market today, Aug 13, 2026 8:00 a.m. ET webcast

Background

This is an SEC 8-K with a Q2 2026 results press release (Item 2.02) for Rockwell Medical, a hemodialysis products supplier.

Company-level read

Ticker impact

$RMTIBullishMedium confidence
Context

Rockwell Medical reported Q2 2026 net sales of $17.8M, gross margin expansion to 18%, and reiterated 2026 guidance.

Expected impact

Near-term bias to the upside if investors view the margin and cash-flow trajectory as credible versus the reiterated 2026 guidance.

Evidence & confidence

The filing provides fresh quarterly datapoints (sales, gross margin, cash flow) plus explicit 2026 guidance ranges, which can re-anchor expectations for a small-cap healthcare name.

Market effects

Sector

Dialysis product suppliers may see read-through demand and pricing confidence if margin and cash-flow improvements persist.

Regional

Limited, company-specific impact likely confined to small-cap healthcare sentiment.

Global

Low, no cross-border or macro linkage beyond healthcare utilization trends.

Counterpoint

What could challenge this read

Despite improving gross margin and operating cash flow, the company still reports net losses and Adjusted EBITDA remains negative, so guidance credibility may be questioned.

Key entities

  • company
    Rockwell Medical, Inc.

    Nasdaq-listed hemodialysis products company reporting Q2 2026 results and reiterating 2026 guidance.

  • regulatory
    Nasdaq Listing Rule 5550(a)(2)

    Minimum bid price compliance matter that the company says has been closed after regaining compliance.

  • customer/partner
    Heritage Dialysis

    Entered into a three-year product purchase agreement announced in May 2026.

  • customer/partner
    aQua Dialysis

    Renewed and extended a product purchase agreement announced in May 2026.

Read at source← All news

Related articles

NOV 3
$RMTIMed

Vantive Announces Agreement to Divest Majority of Hemodialysis Assets and Associated Operations to Rockwell Medical

Vantive agreed to sell most of its hemodialysis assets to Rockwell Medical (RMTI) for $1.2B, focusing on home dialysis and critical care. The deal, expected to close in mid-2027, includes HD concentrates, monitors, and water treatment systems, but excludes Vantive's dialyzer portfolio. Both companies aim to enhance growth and innovation in kidney care.

prnewswire.com2 min
NOV 3
$RMTIHigh

The Rockwell Medical deal leaves Vantive's blood-filtering devices out of the sale.

Vantive will sell its hemodialysis assets to Rockwell Medical (RMTI) for $1.5 billion, focusing on home dialysis and critical care. The deal, expected to close in mid-2027, includes HD monitors, water treatment systems, and related services. Vantive aims to enhance its kidney care platform, while Rockwell Medical plans to invest in the acquired business. Both companies emphasize continuity of care and innovation.

stocktitan.net2 min
NOV 3
$RMTIMedAI 9/10

A factory campus in Italy spanning more than 1 million square feet is part of Rockwell Medical's planned deal.

Rockwell Medical (RMTI) is acquiring Vantive’s hemodialysis business, including products, a manufacturing campus in Italy, and a global customer base. The deal, expected to close mid-2027, aims to establish Rockwell as a leading hemodialysis provider with projected annual revenue of $400M-$450M. Rockwell withdrew its 2026 guidance due to acquisition-related expenses.

stocktitan.net2 min
AUG 14
$RMTIMedAI 8/10

Rockwell Medical (RMTI) Q2 2026 Earnings Call Transcript

Rockwell Medical (RMTI) reported Q2 2026 net sales of $17.8 million, up 11% year over year, with gross profit $3.2 million and gross margin expanding to 18%. Net loss improved to $1.2 million, and operating cash flow turned positive at $2.1 million. FY 2026 guidance: revenue $70 million to $75 million, gross margin 18% to 22%, and adjusted EBITDA $1 million to $2 million. The company completed a 1-for-10 reverse split for Nasdaq bid-price compliance.

fool.com7 min